Skip to main content Accessibility help
×
Home

Predictors of Rectal Carriage of Carbapenem-Resistant Enterobacteriaceae (CRE) among Patients with Known CRE Carriage at Their Next Hospital Encounter

  • Vered Schechner (a1), Tali Kotlovsky (a1), Jalal Tarabeia (a1), Meital Kazma (a1), David Schwartz (a2), Shiri Navon-Venezia (a1) and Yehuda Carmeli (a1)...

Abstract

Background.

Carbapenem-resistant Enterobacteriaceae (CRE) are important extremely drug-resistant pathogens that have emerged during the past decade. Early identification and isolation of carriers are key components of an effective infection control strategy in healthcare facilities. Very little is known about the natural history of CRE carriage. We aimed to determine the predictors of a positive CRE rectal screen test among patients with known CRE carriage screened at their next hospital encounter.

Methods.

A case-control study was conducted. Sixty-six patients who tested positive for CRE carriage were surveyed for CRE rectal carriage at the next hospital encounter; screen-positive patients were compared with screen-negative control patients. Data were extracted from the patients' medical records and from the hospital computerized database.

Results.

Twenty-three case patients and 43 control patients were identified. Predictors for a positive CRE rectal carriage test were (1) prior fluoroquinolone use (odds ratio [OR], 4.27; 95% confidence interval [CI], 1.10–16.6), (2) admission from an institution or another hospital (OR, 4.04; 95% CI, 1.33–12.37), and (3) time interval less than or equal to 3 months since the first positive CRE test (OR, 3.59; 95% CI, 1.24–10.37). Among patients with no predictor variables, the likelihood of having a positive screen test at the next hospital encounter was 1/7. If they had at least 1 predictor, the likelihood increased to 1/2.

Conclusions.

Prior fluoroquinolone use, transfer from another healthcare facility, and admission less than or equal to 3 months since the first CRE isolation are predictors of persistent CRE rectal carriage. These predictors can be used in designing CRE prevention strategies.

Copyright

Corresponding author

Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel, (vereds@tasmc.health.gov.il)

References

Hide All
1. Kitchel, B, Rasheed, JK, Patel, JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:33653370.
2. Sidjabat, HE, Silveira, FP, Potoski, BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009;49:17361738.
3. Goren, MG, Carmeli, Y, Schwaber, MJ, Chmelnitsky, I, Schechner, V, Navon-Venezia, S. Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient. Emerg Infect Dis 2010;16:10141017.
4. Navon-Venezia, S, Leavitt, A, Schwaber, MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818820.
5. Carmeli, Y, Akova, M, Cornaglia, G, et al. Controlling the spread of carbapenemase-producing gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16:102111.
6. Schwaber, MJ, Klarfeld-Lidji, S, Navon-Venezia, S, Schwartz, D, Leavitt, A, Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:10281033.
7. Marchaim, D, Navon-Venezia, S, Schwaber, MJ, Carmeli, Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008;52:14131418.
8. Gasink, LB, Edelstein, PH, Lautenbach, E, Synnestvedt, M, Fish-man, NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae . Infect Control Hosp Epidemiol 2009;30:11801185.
9. Schwaber, MJ; Israel CRE Working Group. Infection control at the national level: containment of an outbreak of carbapenem-resistant Klebsiella pneumoniae (CRKP) in Israeli hospitals. In: Programs and abstracts of the 48th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy I46th Infectious Diseases Society of America Annual Meeting. Washington, DC: American Society for Microbiology, 2008. Abstract K-3509.
10. Kochar, S, Sheard, T, Sharma, R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae . Infect Control Hosp Epidemiol 2009;30:447452.
11. Munoz-Price, LS, De La Cuesta, C, Adams, S, et al. Successful eradication of a monoclonal strain of Klebsiella pneumoniae during a K. pneumoniae carbapenemase-producing K. pneumoniae outbreak in a surgical intensive care unit in Miami, Florida. Infect Control Hosp Epidemiol 2010;31:10741077.
12. Gregory, CJ, Llata, E, Stine, N, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 2010;31:476484.
13. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256260.
14. Ben-David, D, Maor, Y, Keller, N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010;31:620626.
15. Abad, C, Fearday, A, Safdar, N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect 2010;76:97102.
16. Schechner, V, Straus-Robinson, K, Schwartz, D, et al. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J Clin Microbiol 2009;47:32613265.
17. Siegel, JD, Rhinehart, E, Jackson, M, Chiarello, L. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35:S65S164.
18. Lautenbach, E, Strom, BL, Bilker, WB, Patel, JB, Edelstein, PH, Fishman, NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lacta-mase-producing Escherichia coli and Klebsiella pneumoniae . Clin Infect Dis 2001;33:12881294.
19. Lautenbach, E, Metlay, JP, Weiner, MG, et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009;30:1824.
20. Wener, KM, Schechner, V, Gold, HS, Wright, SB, Carmeli, Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother 2010;54:20102016.
21. Falagas, ME, Rafailidis, PI, Kofteridis, D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60: 11241130.
22. Reeves, DS. The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials. J Antimicrob Chemother 1986;18(suppl D):89102.
23. Korten, V, Murray, BE. Impact of the fluoroquinolones on gastrointestinal flora. Drugs 1993;45(suppl 3):125133.
24. Mendes, RE, Bell, JM, Turnidge, JD, et al. Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene. Antimicrob Agents Chemother 2008;52:798799.
25. Endimiani, A, Carias, LL, Hujer, AM, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother 2008;52:26802682.
26. Chmelnitsky, I, Hermesh, O, Navon-Venezia, S, Strahilevitz, J, Carmeli, Y. Detection of aac(6′)-Ib-cr in KPC-producing Klebsiella pneumoniae isolates from Tel Aviv, Israel. J Antimicrob Chemother 2009;64:718722.
27. Kwak, YG, Choi, SH, Choo, EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165169.
28. Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Out comes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:10991106.
29. Bratu, S, Landman, D, Haag, R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165: 14301435.
30. Goren, MG, Navon-Venezia, S, Chmelnitsky, I, Carmeli, Y. Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob Agents Chemother 2010;54:26872691.
31. Bonomo, RA. Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis 2000;31:14141422.
32. Furuno, JP, Hebden, JN, Standiford, HC, et al. Prevalence of methicillin-resistant Staphylococcus aureus and Acinetobacter bau-mannii in a long-term acute care facility. Am J Infect Control 2008;36:468471.
33. Nicolas-Chanoine, MH, Jarlier, V. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 2008; 14(suppl 1): 111116.
34. Urban, C, Mariano, N, Bradford, PA, et al. Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis 2010;66:402406.
35. Endimiani, A, Depasquale, JM, Forero, S, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009;64:11021110.
36. Munoz-Price, LS, Hayden, MK, Lolans, K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31:341347.
37. Ben-David, D, Masarwa, S, Navon-Venezia, S, Smollan, G, Schwaber, MJ; and PAC CRE Working Group. Carbapenem-resistant Enterobacteriaceae (CRE) in post-acute care facilities (PACF) in Israel. In: Programs and abstracts of the 49th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology, 2009. Abstract K-321.
38. Schwaber, MJ, Schechner, V, Kotlovsky, T, et al. Risk factors for rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) on hospital admission. In: Programs and abstracts of the 49th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology, 2009. Abstract K-322.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed